CA2341516A1 - Complexes cationiques d'adenovirus modifie par polymere - Google Patents

Complexes cationiques d'adenovirus modifie par polymere Download PDF

Info

Publication number
CA2341516A1
CA2341516A1 CA002341516A CA2341516A CA2341516A1 CA 2341516 A1 CA2341516 A1 CA 2341516A1 CA 002341516 A CA002341516 A CA 002341516A CA 2341516 A CA2341516 A CA 2341516A CA 2341516 A1 CA2341516 A1 CA 2341516A1
Authority
CA
Canada
Prior art keywords
adenovirus
virus
polymer
glycol
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341516A
Other languages
English (en)
Inventor
Catherine E. O'riordan
Samuel C. Wadsworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341516A1 publication Critical patent/CA2341516A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un complexe d'adénovirus comprend un complexe d'une molécule cationique et d'un adénovirus auquel est lié au moins un polymère de polyalkylène glycol. Le polymère de polyalkylène glycol comprend, sans limitation aucune, le polyéthylène glycol, le méthoxypolyéthylène glycol, le polyméthyléthylène glycol, le polyhydroxypropylène glycol, le polypropylène glycol et le polyméthylpropylène glycol. Le poids moléculaire du polymère varie entre 200 et 20 000 daltons, la préférence se situant entre 2 000 et 12 000 Daltons. L'adénovirus est de préférence un vecteur adénoviral de recombinaison tel qu'un vecteur viral de recombinaison contenant un transgène. Le polymère est lié, directement ou indirectement, à la particule virale par un système covalent ou non covalent. La molécule cationique est de préférence un polymère cationique, tel que le DEAE-Dextran, ou un lipide cationique. L'invention concerne également une composition contenant le complexe d'adénovirus et un support.
CA002341516A 1998-08-24 1999-08-23 Complexes cationiques d'adenovirus modifie par polymere Abandoned CA2341516A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9765398P 1998-08-24 1998-08-24
US60/097,653 1998-08-24
PCT/US1999/019162 WO2000011202A1 (fr) 1998-08-24 1999-08-23 Complexes cationiques d'adenovirus modifie par polymere

Publications (1)

Publication Number Publication Date
CA2341516A1 true CA2341516A1 (fr) 2000-03-02

Family

ID=22264491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341516A Abandoned CA2341516A1 (fr) 1998-08-24 1999-08-23 Complexes cationiques d'adenovirus modifie par polymere

Country Status (5)

Country Link
EP (1) EP1108048A1 (fr)
JP (1) JP2002523054A (fr)
AU (1) AU5685799A (fr)
CA (1) CA2341516A1 (fr)
WO (1) WO2000011202A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033886A1 (fr) * 1998-12-04 2000-06-15 Genzyme Corporation Complexes de poudres seches destines a la fourniture de genes
US7279318B1 (en) * 1999-06-09 2007-10-09 Hybrid Systems Limited Modification of biological elements
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
CN1880457B (zh) * 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
WO2003049763A1 (fr) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition pour la conservation de virus
ATE506445T1 (de) * 2003-02-17 2011-05-15 Fuso Pharmaceutical Ind Neuartiger virusvektor
US20080107629A1 (en) * 2006-09-29 2008-05-08 Canji, Inc. Methods and compositions for gene therapy
WO2009053700A1 (fr) * 2007-10-23 2009-04-30 Cancer Research Technology Limited Modification d'entités biologiques contenant des acides nucléiques
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2015163622A1 (fr) * 2014-04-22 2015-10-29 한양대학교 산학협력단 Composite polymère-virus sensible au ph et bioréducteur pour le traitement du cancer
US11529414B2 (en) * 2020-06-23 2022-12-20 Orbis Health Solutions, Llc Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
AU745056B2 (en) * 1997-04-03 2002-03-07 Genzyme Corporation Polymer-modified viruses

Also Published As

Publication number Publication date
WO2000011202A1 (fr) 2000-03-02
AU5685799A (en) 2000-03-14
EP1108048A1 (fr) 2001-06-20
JP2002523054A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
US5928944A (en) Method of adenoviral-medicated cell transfection
Mével et al. Chemical modification of the adeno-associated virus capsid to improve gene delivery
ES2246533T3 (es) Fibra adenovirica modificada y adenovirus dianas.
Xu et al. The contribution of poly-L-lysine, epidermal growth factor and streptavidin to EGF/PLL/DNA polyplex formation
JP2001505054A (ja) キメラアデノウイルスベクター
US5981275A (en) Transgene expression system for increased persistence
Guerette et al. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig
US20200224219A1 (en) Mutated adeno-associated viral capsid proteins for chemical coupling of ligands, nanoparticles or drugs via thioether binding and production method thereof
CA2341516A1 (fr) Complexes cationiques d'adenovirus modifie par polymere
US5962429A (en) Complexes of adenovirus with cationic molecules
JP2002508967A (ja) 修飾カプシド蛋白を有するアデノウイルスベクター
AU745056B2 (en) Polymer-modified viruses
JP2003534805A (ja) 変化した親和性を有する改変ウシアデノウイルス
Jiang et al. Engineering polypeptide coatings to augment gene transduction and in vivo stability of adenoviruses
US6569426B2 (en) Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivity
US6086870A (en) Co-precipitates of adenovirus with metal salts
AU2004200869A1 (en) Cationic complexes of polymer-modified adenovirus
EP1363676B1 (fr) Procede pour renforcer l'efficacite de l'apport d'un acide nucleique therapeutique
Klink et al. Gene therapy of cystic fibrosis (CF) airways: a review emphasizing targeting with lactose
SK70999A3 (en) Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent
WO2000033886A1 (fr) Complexes de poudres seches destines a la fourniture de genes
AU3142902A (en) Novel transgene expression system for increased persistence

Legal Events

Date Code Title Description
FZDE Dead